Quantum-Si Incorporated ( (QSI) ) has released its Q3 earnings. Here is a breakdown of the information Quantum-Si Incorporated presented to its investors.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Quantum-Si Incorporated is a proteomics technology company that specializes in redefining protein analysis through single-molecule detection, aiming to make protein analysis simpler and more informative. In its third quarter 2025 earnings report, Quantum-Si announced a revenue of $552,000 and highlighted successful sequencing on a prototype Proteus system, with its development program remaining on track. The company also emphasized the success of its instrument placement program and the launch of its version 4 Sequencing Kit.
Key financial metrics from the report include a gross profit of $194,000 and a gross margin of 35% for the third quarter. Operating expenses increased to $40.0 million compared to the previous year, while adjusted operating expenses decreased to $21.4 million. The company reported a net loss of $35.7 million for the quarter, with adjusted EBITDA at negative $20.1 million.
Strategically, Quantum-Si is focusing on expanding its customer base through various instrument acquisition options and is on track to launch its version 3 Library Prep Kit by the end of 2025. The company is also preparing for the future launch of its transformative Proteus platform in the second half of 2026.
Looking ahead, Quantum-Si management remains optimistic about increasing awareness and adoption of its technology, and it plans to provide further updates on its development initiatives at the upcoming Investor and Analyst Day on November 19, 2025.